
HTGF invests in AudioCure Pharma
High-Tech Gründerfonds (HTGF) and business angel Dr Schumacher have provided German drugs candidate developer AudioCure Pharma with seed funding.
HTGF typically invests €500,000 in first backings and allocates up to €1.5m for further funding.
The investment will concentrate on the development of a treatment for acute and chronic hearing impairments.
Company
AudioCure Pharma was founded in Berlin in August 2010 by university professor and doctor of medicine Hans Rommelspacher.
Rommelspacher has been studying the primary compound to be used in the drug for 20 years. In the past few years he embarked on extensive structure-activity experiments and proved the therapeutic potential of the drug.
AudioCure Pharma is part of the NeuroPro Alliance research network alongside NanoPet Pharma Berlin and Wildau Technical University of Applied Sciences. The network is partially financed by the German Federal Ministry of Education and Research.
People
Dr Martin Pfister is an investment manager at HTGF.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater